J&J unblinds prostate cancer drug study; Aegerion names new CEO

@FierceBiotech: Four drugs look to pass FDA muster this month. Report | Follow @FierceBiotech

@JohnCFierce: Seattle Genetics CEO did a good job softening the blow on its trial failure; shares down about 18% anyway. | Follow @FierceBiotech

> J&J decided to unblind its Phase III study of the prostate cancer drug abiraterone acetate after the monitoring committee determined that the patients in the placebo group should be offered the therapy. The trial enrolled 1,195 patients. Report

> Aegerion Pharmaceuticals named Marc Beer, the founding CEO of ViaCell, as both CEO and a member of the board of directors. Aegerion release

> Ariad Pharmaceuticals and Cyclacel Pharmaceuticals each announced plans to move blood cancer therapies into late-stage trials. Story

> Athersys is pocketing a $3 million upfront after it agreed to provide RTI Biologics access to its Multipotent Adult Progenitor Cell technologies. RTI release

And Finally... Scientists say they've found a plant that can clone itself in order to survive environmental chaos, a helpful lesson for surviving climate change. Story

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."